Skip to main content
Premium Trial:

Request an Annual Quote

Sedia Biosciences Merges With Floragenex

NEW YORK (GenomeWeb) – Point-of-care diagnostics developer Sedia Biosciences has merged with genomic testing services provider Floragenex, the companies announced today.

Floragenex will now operate as a newly established subsidiary of Sedia, and will continue to offer its genomic services and solutions to life scientists. Sedia will also continue to offer its own Asanté assays for HIV and other infectious agents. Sedia CEO Roger Gale will remain CEO of the combined companies.

Additional details of the transaction were not disclosed.

"The merger with Sedia Biosciences will help expand Floragenex's expertise in the product and diagnostic spaces while helping to grow our existing genomic services business," Floragenex CEO Rick Nipper, who will continue to oversee the Floragenex subsidiary, said in a statement. 

Sedia President and CSO Ronald Mink added that the combination of the two companies' expertise "will assist Sedia's expansion into novel molecular diagnostic products to supplement and enhance our current product lines, and allow further expansion into plant and animal testing."